Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 29, 2024

SELL
$48.48 - $57.85 $5,284 - $6,305
-109 Reduced 0.55%
19,859 $1.02 Million
Q3 2023

Oct 25, 2023

BUY
$57.89 - $64.73 $30,971 - $34,630
535 Added 2.75%
19,968 $1.16 Million
Q2 2023

Jul 28, 2023

SELL
$63.71 - $70.74 $2,038 - $2,263
-32 Reduced 0.16%
19,433 $1.24 Million
Q1 2023

Apr 25, 2023

SELL
$65.71 - $74.53 $11,893 - $13,489
-181 Reduced 0.92%
19,465 $1.35 Million
Q4 2022

Feb 03, 2023

SELL
$68.48 - $81.09 $100,528 - $119,040
-1,468 Reduced 6.95%
19,646 $1.41 Million
Q3 2022

Nov 04, 2022

SELL
$0.13 - $76.84 $10 - $5,916
-77 Reduced 0.36%
21,114 $1.5 Million
Q2 2022

Aug 04, 2022

SELL
$72.62 - $79.98 $14,741 - $16,235
-203 Reduced 0.95%
21,191 $1.63 Million
Q1 2022

Apr 25, 2022

SELL
$61.48 - $73.72 $12,664 - $15,186
-206 Reduced 0.95%
21,394 $1.56 Million
Q4 2021

Jan 21, 2022

BUY
$53.63 - $62.52 $25,849 - $30,134
482 Added 2.28%
21,600 $1.35 Million
Q3 2021

Oct 27, 2021

BUY
$59.17 - $69.31 $42,779 - $50,111
723 Added 3.54%
21,118 $1.25 Million
Q2 2021

Jul 26, 2021

BUY
$61.91 - $67.42 $101,470 - $110,501
1,639 Added 8.74%
20,395 $1.36 Million
Q1 2021

Apr 23, 2021

BUY
$59.34 - $66.74 $28,898 - $32,502
487 Added 2.67%
18,756 $1.18 Million
Q4 2020

Jan 22, 2021

SELL
$57.74 - $65.43 $4,619 - $5,234
-80 Reduced 0.44%
18,269 $1.13 Million
Q3 2020

Oct 20, 2020

BUY
$57.43 - $63.64 $16,712 - $18,519
291 Added 1.61%
18,349 $1.11 Million
Q2 2020

Jul 22, 2020

BUY
$54.82 - $64.09 $23,462 - $27,430
428 Added 2.43%
18,058 $1.06 Million
Q1 2020

Apr 24, 2020

SELL
$46.4 - $67.43 $8,444 - $12,272
-182 Reduced 1.02%
17,630 $983,000
Q4 2019

Jan 24, 2020

BUY
$49.21 - $64.19 $876,528 - $1.14 Million
17,812 New
17,812 $1.14 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Taylor Frigon Capital Management LLC Portfolio

Follow Taylor Frigon Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Taylor Frigon Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Taylor Frigon Capital Management LLC with notifications on news.